Thyroid awareness month

Ipsen to Acquire Albireo for USD 952 Million Ipsen, a French pharmaceutical company, has offered USD 42 per share for the US biotech Albireo and its rare disease treatment Bylvay, continuing a recent spree of merger and acquisition activity. Albireo, a Boston-based business, is valued at USD 952 million under th...

The newly approved drug teprotumumab can offer hope to adults with thyroid eye disease, a rare and potentially blinding condition. It's the first treatment specifically approved for thyroid eye disease. The drug of Horizon Therapeutics was approved by the U.S. Food and Drug Administration and is set to be marketed ...

Musculoskeletal disorders are one of the most common disorders affecting a significant proportion of the population worldwide. They can have severe long-term pain, high levels of physical disability, various types of psychological distress, and reduced quality of life. As per the WHO (2022), musculoskeletal conditi...